On the stock market since 2016, it operates in the world of health and science. It has 112 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
An average decline of 100% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
The cash pile is strong; debt and other items pull the grade toward the middle.
Clearly below the class average.
Clearly below the class average.
The stock has been running stronger than the market lately.
Business Quality: Profit power and business quality trail similar companies in the sector.
Growth: Sales growth trails the sector average.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: The profit kept from each sale is thin.
The stock trades 54% below its peak. The market has trimmed its expectations for the company.
There is $756.5M in the vault; even if every debt were paid off, $756.5M would remain.
A loss of $155.2M against $0 in annual sales.
This stock swings about 3 times as much as the market average. Big rallies — and big drops — can both happen fast.
On our five-subject report card, SYRE sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: SYRE is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.